What is the 13F Pro Quality Score for NRXP?

13F Pro ranks NRX Pharmaceuticals, Inc. (NRXP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRXP's current score at https://13fpro.ai/research/NRXP (free sign-up required for the full ranking).

Which hedge funds own the most NRXP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NRXP include B Group,, VANGUARD CAPITAL MANAGEMENT, AdvisorShares Investments. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NRXP as soon as new 13F filings post.

Where does 13F Pro source NRXP data?

All NRX Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. NRX Pharmaceuticals, Inc. files with the SEC under CIK 1719406. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRXP in?

NRX Pharmaceuticals, Inc. (NRXP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRXP research updated on 13F Pro?

NRXP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NRX Pharmaceuticals, Inc.(NRXP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1719406 NRXP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NRXP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NRX Pharmaceuticals, Inc. (NRXP), a Healthcare sector company. NRXP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), NRX Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-1.4M, free cash flow of $-4.3M. Top institutional holders of NRXP by reported 13-F value include B Group,, VANGUARD CAPITAL MANAGEMENT, AdvisorShares Investments, based on the most recent SEC filings. NRXP trades on the Nasdaq exchange and files with the SEC under CIK 1719406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRX Pharmaceuticals, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$1.1M

Net Income

Q1 2026

$-1.4M

Free Cash Flow

Q1 2026

$-4.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$1.2MFY 2025

FY19 —FY22 —FY24 $0.00FY25 $1.2M

Net Income

-13.9% YoY

$-28.6MFY 2025

FY19 $408.4KFY22 $-39.8MFY24 $-25.1MFY25 $-28.6M

Operating Income

+12.3% YoY

$-16.2MFY 2025

FY19 $-713.2KFY22 $-44.3MFY24 $-18.5MFY25 $-16.2M

EPS (Diluted)

—FY 2025

FY19 —FY22 $-0.60FY24 —FY25 —

Total Assets

+254.9% YoY

$13.0MFY 2025

FY19 $32.1MFY22 $25.8MFY24 $3.7MFY25 $13.0M

Total Debt

—FY 2025

FY19 —FY22 $18.2MFY24 —FY25 —

Op. Cash Flow

-32.7% YoY

$-14.1MFY 2025

FY19 $-792.7KFY22 $-39.8MFY24 $-10.6MFY25 $-14.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2019	FY 2017
Revenue	$1.2M	$0.00	—	—	—
Net Income	$-28.6M -13.9%	$-25.1M +36.8%	$-39.8M -9833.4%	$408.4K	—
Operating Income	$-16.2M +12.3%	$-18.5M +58.3%	$-44.3M -6116.5%	$-713.2K	—
EPS (Diluted)	—	—	$-0.60	—	—
Total Assets	$13.0M +254.9%	$3.7M -85.9%	$25.8M -19.5%	$32.1M -53.9%	$69.6M
Total Debt	—	—	$18.2M	—	—
Operating Cash Flow	$-14.1M -32.7%	$-10.6M +73.2%	$-39.8M -4914.9%	$-792.7K	—

AI Insight: NRXP Financial Trends

NRX remains pre-revenue with persistent operating losses and deepening negative equity; Q1 2026 shows marginal revenue emergence but cash burn unabated.

• Revenue inflection beginning: $0M through Q3 2025, then $1M in Q1 2026. First top-line recognition after years of zero sales.

• Negative equity deteriorated from $-6M (Q3 2023) to $-36M (Q2 2025), though improved to $-14M by Q1 2026.

• Operating cash burn remains consistent: $3–5M per quarter, with no cash flow inflection despite revenue emergence.

⚠ Net loss swung wildly—$18M loss in Q2 2025 versus $1M loss in Q1 2026—suggests volatile cost structure or one-time charges.

⚠ Sustainability risk: Negative equity of $14M in Q1 2026 with $4M quarterly cash burn threatens runway without capital injection.

AI Insight: NRXP Ratio Trends

Insufficient data to assess trend; only Q1 2026 shows metrics, revealing negative profitability but no historical context.

• Q1 2026 net profit margin of -133.9% and ROA of -48.1% indicate significant operating losses.

⚠ No prior-quarter ratios available to establish trajectory or seasonality patterns in losses.

Get alerted when NRXP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NRX Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRXP

B Group, Inc.
$6.4M3,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.5M1,160,184 sh
AdvisorShares Investments LLC
$895.6K420,467 sh
COMMONWEALTH EQUITY SERVICES, LLC
$846.5K397,431 sh
GEODE CAPITAL MANAGEMENT, LLC
$660.6K310,112 sh
VANGUARD FIDUCIARY TRUST CO
$361.2K169,580 sh
Bleakley Financial Group, LLC
$249.6K117,204 sh
JANE STREET GROUP, LLC
$212.8K99,900 sh
BlackRock, Inc.
$210.9K98,995 sh
STATE STREET CORP
$185.3K86,984 sh

Fund	Value	Shares
B Group, Inc.	$6.4M	3,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$2.5M	1,160,184
AdvisorShares Investments LLC	$895.6K	420,467
COMMONWEALTH EQUITY SERVICES, LLC	$846.5K	397,431
GEODE CAPITAL MANAGEMENT, LLC	$660.6K	310,112
VANGUARD FIDUCIARY TRUST CO	$361.2K	169,580
Bleakley Financial Group, LLC	$249.6K	117,204
JANE STREET GROUP, LLC	$212.8K	99,900
BlackRock, Inc.	$210.9K	98,995
STATE STREET CORP	$185.3K	86,984

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRXP on your watchlist

Track score changes the day NRX Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRXP a good stock to buy?

13F Pro's AI-powered analysis of NRX Pharmaceuticals, Inc. (NRXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRXP are available on the NRXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NRXP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NRX Pharmaceuticals, Inc.'s investment landscape.